Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles

Pharm Res. 2020 Apr 14;37(4):82. doi: 10.1007/s11095-020-02794-z.

Abstract

Purpose: Myricetin (MYR) flavonoid is well-recognized for its antioxidant, anti-inflammatory and anti-tumor potential. Introducing nanomedicine was the ultimate resort to solve the imperfections of this nutraceutical, namely solubility, stability and delivery issues. The study, thus, aims at developing inhalable microparticles comprising MYR solid lipid nanoparticles (SLNs) for lung cancer therapy.

Methods: A two-step preparation procedure starting with complexation of MYR with the phospholipid Lipoid-S100, followed by nanoencapsulation in Gelucire-based, surfactant-free SLNs was developed. SLNs were characterized in terms of physicochemical properties, MYR loading, release behavior as well as anti-tumor potential and cellular uptake. Respirable microparticles were then obtained by spray drying SLNs with carbohydrate carriers. Their size, flowability and pulmonary deposition pattern were assessed.

Results: Optimized SLNs were 75.98 nm in diameter with a zeta-potential of -22.5 mV, and an encapsulation efficiency of 84.5%. Attempts to ameliorate drug loading implicate MYR-phospholipid complexation (MYR-PH-CPX) prior to its entrapment in SLNs, which ensured 5-fold increase in drug loading. Viability assays were modified to guarantee MYR chemical stability. Superior antitumor activity of MYR-phospholipid-complex and 3-fold reduction in IC50 were accomplished with MYR-SLNs. This could be related to enhanced cellular uptake revealed by confocal imaging and doubled fluorescence intensity. SLNs entrapping MYR-PH-CPX were spray-dried with carbohydrate carriers to produce respirable microparticles. The latter ensured MMAD of 2.39 μm and span index of 1.84, in addition to good flowability and > 80% release over 8 h. Deposition experiments revealed MMAD of 2.77 μm, FPF of 81.23 and EF of 93% indicating particle deposition in the targeted bronchial region.

Conclusions: The study highlights the ability of phospholipid-complex on the nanoencapsulation, cellular uptake and antitumor activity of MYR. Formulation of respirable microparticles gives promises of efficacious therapy of lung carcinoma.

Keywords: Gelucires; drug-phospholipid complex; lipoid S100; nutraceuticals; phytomedicine; solid lipid nanoparticles.

MeSH terms

  • A549 Cells
  • Administration, Inhalation
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology
  • Cell Survival / drug effects
  • Drug Carriers / chemistry*
  • Drug Compounding
  • Drug Liberation
  • Flavonoids / administration & dosage*
  • Flavonoids / metabolism
  • Flavonoids / pharmacology
  • Humans
  • Lung Neoplasms / drug therapy*
  • Nanoparticles / chemistry*
  • Particle Size
  • Phospholipids / chemistry*
  • Solubility
  • Surface Properties
  • Tissue Distribution

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Flavonoids
  • Phospholipids
  • myricetin